Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 22 |
| Active Pipeline (Recruiting Now) | 7 (3) |
| Completed vs Stopped Early | 9 / 6 (27.3%) |
| Median Closed Actual Enrollment | 56 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| MD Anderson Cancer Center | Houston, TX | 6 |
| Memorial Sloan Kettering Cancer Center | New York, NY | 5 |
| Duke University Medical Center | Durham, NC | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06465953 | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes | Phase III | RECRUITING |
| NCT04164901 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | Phase III | ACTIVE NOT RECRUITING |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. | Phase III | ACTIVE NOT RECRUITING |
| NCT05820880 | Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension | Phase III | COMPLETED |
| NCT04817761 | SPARK-ALL: Calaspargase Pegol in Adults With ALL | Phase II/III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Institut de Recherches Internationales Servier Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.